Associations - KEAP1 mutation

KEAP1 mutation KEAP1 mutation	Non Small Cell Lung Cancer NSCLC	KEAP1 mutation KEAP1 mutation	Non Small Cell Lung Cancer NSCLC	DRP-104 Sensitive: B - Late Trials	DRP-104 Sensitive: B - Late Trials
KEAP1 mutation KEAP1 mutation	Non Small Cell Lung Cancer NSCLC	KEAP1 mutation KEAP1 mutation	Non Small Cell Lung Cancer NSCLC	durvalumab Resistant: B - Late Trials	durvalumab Resistant: B - Late Trials
KEAP1 mutation KEAP1 mutation	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	KEAP1 mutation KEAP1 mutation	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	CB-228 Sensitive: C2 – Inclusion Criteria	CB-228 Sensitive: C2 – Inclusion Criteria
KEAP1 mutation KEAP1 mutation	Non Small Cell Lung Cancer NSCLC	KEAP1 mutation KEAP1 mutation	Non Small Cell Lung Cancer NSCLC	rivoceranib + camrelizumab Sensitive: C3 – Early Trials	rivoceranib + camrelizumab Sensitive: C3 – Early Trials
KEAP1 mutation KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	KEAP1 mutation KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	docetaxel Resistant: C3 – Early Trials	docetaxel Resistant: C3 – Early Trials
KEAP1 mutation KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	KEAP1 mutation KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Resistant: C3 – Early Trials	atezolizumab Resistant: C3 – Early Trials
KEAP1 mutation KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	KEAP1 mutation KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	rivoceranib + camrelizumab Sensitive: C3 – Early Trials	rivoceranib + camrelizumab Sensitive: C3 – Early Trials
KEAP1 mutation KEAP1 mutation	Non Small Cell Lung Cancer NSCLC	KEAP1 mutation KEAP1 mutation	Non Small Cell Lung Cancer NSCLC	atezolizumab Resistant: C3 – Early Trials	atezolizumab Resistant: C3 – Early Trials
KEAP1 mutation KEAP1 mutation	Non Small Cell Lung Cancer NSCLC	KEAP1 mutation KEAP1 mutation	Non Small Cell Lung Cancer NSCLC	PD-L1 inhibitor Sensitive: C3 – Early Trials	PD-L1 inhibitor Sensitive: C3 – Early Trials
KEAP1 mutation KEAP1 mutation	Non Small Cell Lung Cancer NSCLC	KEAP1 mutation KEAP1 mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
KEAP1 mutation KEAP1 mutation	Solid Tumor Solid Tumor	KEAP1 mutation KEAP1 mutation	Solid Tumor Solid Tumor	IPN60090 Sensitive: C3 – Early Trials	IPN60090 Sensitive: C3 – Early Trials
KEAP1 mutation KEAP1 mutation	Lung Adenocarcinoma LUAD	KEAP1 mutation KEAP1 mutation	Lung Adenocarcinoma LUAD	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
KEAP1 mutation KEAP1 mutation	Lung Adenocarcinoma LUAD	KEAP1 mutation KEAP1 mutation	Lung Adenocarcinoma LUAD	DRP-104 Sensitive: D – Preclinical	DRP-104 Sensitive: D – Preclinical
KEAP1 mutation KEAP1 mutation	Lung Cancer Lung Cancer	KEAP1 mutation KEAP1 mutation	Lung Cancer Lung Cancer	IPN60090 Sensitive: D – Preclinical	IPN60090 Sensitive: D – Preclinical